Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16451092 | 1.00 | ATM (0.36) | ATM | |
| SCHEMBL16451091 | 1.00 | ATM (0.36) | ATM | |
| SCHEMBL9611078 | 0.88 | ATM (0.38) | ATM | |
| SCHEMBL16451085 | 0.88 | ATM (0.38) | ATM | |
| SCHEMBL16451090 | 0.88 | ATM (0.38) | ATM | |
| SCHEMBL9611093 | 0.84 | — | — | |
| SCHEMBL22959712 | 0.82 | ADORA2A (0.34) | — | |
| SCHEMBL24777623 | 0.82 | ATM (0.37) | ATM | |
| SCHEMBL10205027 | 0.82 | ATM (0.37) | ATM | |
| SCHEMBL9611092 | 0.78 | ATM (0.48) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20170326250-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2017-11-16 | — | — | US | disclosed |
| US-8940768-B2 | Antifungal triazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | disclosed |
| US-20120309771-A1 | NOVEL ANTIFUNGAL TRIAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326250-A1 | CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF | MKI67, CCNI, PA2G4 | ATM 3755/4885 |
| US-20120309771-A1 | NOVEL ANTIFUNGAL TRIAZOLE DERIVATIVES | ERG28, CYP51A1, DPM1 | ATM 1184/4885 |
| US-11771697-B2 | Small molecule degraders of polybromo-1 (PBRM1) | PBRM1, SMARCC1, SMARCC2 | ATM 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.